+1 Recommend
1 collections
      Call for Papers in Kidney and Blood Pressure ResearchKidney Function and Omics Science

      Submission Deadline: December 20, 2023

      Submit now

      • Record: found
      • Abstract: found
      • Article: found

      Influence of Early-Onset Peritonitis on Mortality and Clinical Outcomes in ESRD Patients with Diabetes Mellitus on Peritoneal Dialysis: A Retrospective Multicenter Study


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Introduction: The impact of early-onset peritonitis (EOP) on patients with diabetes undergoing peritoneal dialysis (PD) has not been adequately addressed. We therefore sought to investigate the effects of EOP on the therapeutic response to management and long-term prognostic outcomes in patients with diabetes undergoing PD. Methods: For this retrospective cohort study, we analyzed the data for patients with end-stage renal disease, who were also suffering from diabetes mellitus and had undergone PD between January 1, 2013, and December 31, 2018. EOP was defined as the first episode of peritoneal dialysis-related peritonitis (PDAP) occurring within 12 months of PD initiation. All patients were divided into an EOP group and a later-onset peritonitis (LOP) group. Clinical data, treatment results, and outcomes were compared between groups. Results: Ultimately, 202 patients were enrolled for the analysis. Compared to the EOP group, the LOP group had more Streptococcus ( p = 0.033) and Pseudomonas ( p = 0.048). Patients with diabetes in the EOP group were less likely to have PDAP-related death (OR 0.13, CI: 0.02–0.82, p = 0.030). Patients with diabetes in the EOP group were more likely to have multiple episodes of PDAP and had higher rates of technical failure and poorer patient survival than those in the LOP group, as indicated by Kaplan-Meier analysis ( p = 0.019, p = 0.004, and p < 0.001). In the multivariate Cox proportional hazards model, EOP was a significant predictor for multiple PDAP (HR 4.20, CI: 1.48–11.96, p = 0.007), technical failure (HR 6.37, CI: 2.21–18.38, p = 0.001), and poorer patient survival (HR 3.09, CI: 1.45–6.58, p = 0.003). Conclusions: The occurrence of EOP is significantly associated with lower rates of PDAP-related death and poorer clinical outcomes in patients with diabetes undergoing PD.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Diagnosis and Classification of Diabetes Mellitus

          DEFINITION AND DESCRIPTION OF DIABETES MELLITUS Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the β-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues. Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia. Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia. Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome. Long-term complications of diabetes include retinopathy with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; and autonomic neuropathy causing gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction. Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, peripheral arterial, and cerebrovascular disease. Hypertension and abnormalities of lipoprotein metabolism are often found in people with diabetes. The vast majority of cases of diabetes fall into two broad etiopathogenetic categories (discussed in greater detail below). In one category, type 1 diabetes, the cause is an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. In the other, much more prevalent category, type 2 diabetes, the cause is a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. In the latter category, a degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected. During this asymptomatic period, it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load or by A1C. The degree of hyperglycemia (if any) may change over time, depending on the extent of the underlying disease process (Fig. 1). A disease process may be present but may not have progressed far enough to cause hyperglycemia. The same disease process can cause impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) without fulfilling the criteria for the diagnosis of diabetes. In some individuals with diabetes, adequate glycemic control can be achieved with weight reduction, exercise, and/or oral glucose-lowering agents. These individuals therefore do not require insulin. Other individuals who have some residual insulin secretion but require exogenous insulin for adequate glycemic control can survive without it. Individuals with extensive β-cell destruction and therefore no residual insulin secretion require insulin for survival. The severity of the metabolic abnormality can progress, regress, or stay the same. Thus, the degree of hyperglycemia reflects the severity of the underlying metabolic process and its treatment more than the nature of the process itself. Figure 1 Disorders of glycemia: etiologic types and stages. *Even after presenting in ketoacidosis, these patients can briefly return to normoglycemia without requiring continuous therapy (i.e., “honeymoon” remission); **in rare instances, patients in these categories (e.g., Vacor toxicity, type 1 diabetes presenting in pregnancy) may require insulin for survival. CLASSIFICATION OF DIABETES MELLITUS AND OTHER CATEGORIES OF GLUCOSE REGULATION Assigning a type of diabetes to an individual often depends on the circumstances present at the time of diagnosis, and many diabetic individuals do not easily fit into a single class. For example, a person diagnosed with gestational diabetes mellitus (GDM) may continue to be hyperglycemic after delivery and may be determined to have, in fact, type 2 diabetes. Alternatively, a person who acquires diabetes because of large doses of exogenous steroids may become normoglycemic once the glucocorticoids are discontinued, but then may develop diabetes many years later after recurrent episodes of pancreatitis. Another example would be a person treated with thiazides who develops diabetes years later. Because thiazides in themselves seldom cause severe hyperglycemia, such individuals probably have type 2 diabetes that is exacerbated by the drug. Thus, for the clinician and patient, it is less important to label the particular type of diabetes than it is to understand the pathogenesis of the hyperglycemia and to treat it effectively. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) Immune-mediated diabetes. This form of diabetes, which accounts for only 5–10% of those with diabetes, previously encompassed by the terms insulin-dependent diabetes or juvenile-onset diabetes, results from a cellular-mediated autoimmune destruction of the β-cells of the pancreas. Markers of the immune destruction of the β-cell include islet cell autoantibodies, autoantibodies to insulin, autoantibodies to GAD (GAD65), and autoantibodies to the tyrosine phosphatases IA-2 and IA-2β. One and usually more of these autoantibodies are present in 85–90% of individuals when fasting hyperglycemia is initially detected. Also, the disease has strong HLA associations, with linkage to the DQA and DQB genes, and it is influenced by the DRB genes. These HLA-DR/DQ alleles can be either predisposing or protective. In this form of diabetes, the rate of β-cell destruction is quite variable, being rapid in some individuals (mainly infants and children) and slow in others (mainly adults). Some patients, particularly children and adolescents, may present with ketoacidosis as the first manifestation of the disease. Others have modest fasting hyperglycemia that can rapidly change to severe hyperglycemia and/or ketoacidosis in the presence of infection or other stress. Still others, particularly adults, may retain residual β-cell function sufficient to prevent ketoacidosis for many years; such individuals eventually become dependent on insulin for survival and are at risk for ketoacidosis. At this latter stage of the disease, there is little or no insulin secretion, as manifested by low or undetectable levels of plasma C-peptide. Immune-mediated diabetes commonly occurs in childhood and adolescence, but it can occur at any age, even in the 8th and 9th decades of life. Autoimmune destruction of β-cells has multiple genetic predispositions and is also related to environmental factors that are still poorly defined. Although patients are rarely obese when they present with this type of diabetes, the presence of obesity is not incompatible with the diagnosis. These patients are also prone to other autoimmune disorders such as Graves' disease, Hashimoto's thyroiditis, Addison's disease, vitiligo, celiac sprue, autoimmune hepatitis, myasthenia gravis, and pernicious anemia. Idiopathic diabetes. Some forms of type 1 diabetes have no known etiologies. Some of these patients have permanent insulinopenia and are prone to ketoacidosis, but have no evidence of autoimmunity. Although only a minority of patients with type 1 diabetes fall into this category, of those who do, most are of African or Asian ancestry. Individuals with this form of diabetes suffer from episodic ketoacidosis and exhibit varying degrees of insulin deficiency between episodes. This form of diabetes is strongly inherited, lacks immunological evidence for β-cell autoimmunity, and is not HLA associated. An absolute requirement for insulin replacement therapy in affected patients may come and go. Type 2 diabetes (ranging from predominantly insulin resistance with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance) This form of diabetes, which accounts for ∼90–95% of those with diabetes, previously referred to as non–insulin-dependent diabetes, type 2 diabetes, or adult-onset diabetes, encompasses individuals who have insulin resistance and usually have relative (rather than absolute) insulin deficiency At least initially, and often throughout their lifetime, these individuals do not need insulin treatment to survive. There are probably many different causes of this form of diabetes. Although the specific etiologies are not known, autoimmune destruction of β-cells does not occur, and patients do not have any of the other causes of diabetes listed above or below. Most patients with this form of diabetes are obese, and obesity itself causes some degree of insulin resistance. Patients who are not obese by traditional weight criteria may have an increased percentage of body fat distributed predominantly in the abdominal region. Ketoacidosis seldom occurs spontaneously in this type of diabetes; when seen, it usually arises in association with the stress of another illness such as infection. This form of diabetes frequently goes undiagnosed for many years because the hyperglycemia develops gradually and at earlier stages is often not severe enough for the patient to notice any of the classic symptoms of diabetes. Nevertheless, such patients are at increased risk of developing macrovascular and microvascular complications. Whereas patients with this form of diabetes may have insulin levels that appear normal or elevated, the higher blood glucose levels in these diabetic patients would be expected to result in even higher insulin values had their β-cell function been normal. Thus, insulin secretion is defective in these patients and insufficient to compensate for insulin resistance. Insulin resistance may improve with weight reduction and/or pharmacological treatment of hyperglycemia but is seldom restored to normal. The risk of developing this form of diabetes increases with age, obesity, and lack of physical activity. It occurs more frequently in women with prior GDM and in individuals with hypertension or dyslipidemia, and its frequency varies in different racial/ethnic subgroups. It is often associated with a strong genetic predisposition, more so than is the autoimmune form of type 1 diabetes. However, the genetics of this form of diabetes are complex and not fully defined. Other specific types of diabetes Genetic defects of the β-cell. Several forms of diabetes are associated with monogenetic defects in β-cell function. These forms of diabetes are frequently characterized by onset of hyperglycemia at an early age (generally before age 25 years). They are referred to as maturity-onset diabetes of the young (MODY) and are characterized by impaired insulin secretion with minimal or no defects in insulin action. They are inherited in an autosomal dominant pattern. Abnormalities at six genetic loci on different chromosomes have been identified to date. The most common form is associated with mutations on chromosome 12 in a hepatic transcription factor referred to as hepatocyte nuclear factor (HNF)-1α. A second form is associated with mutations in the glucokinase gene on chromosome 7p and results in a defective glucokinase molecule. Glucokinase converts glucose to glucose-6-phosphate, the metabolism of which, in turn, stimulates insulin secretion by the β-cell. Thus, glucokinase serves as the “glucose sensor” for the β-cell. Because of defects in the glucokinase gene, increased plasma levels of glucose are necessary to elicit normal levels of insulin secretion. The less common forms result from mutations in other transcription factors, including HNF-4α, HNF-1β, insulin promoter factor (IPF)-1, and NeuroD1. Diabetes diagnosed in the first 6 months of life has been shown not to be typical autoimmune type 1 diabetes. This so-called neonatal diabetes can either be transient or permanent. The most common genetic defect causing transient disease is a defect on ZAC/HYAMI imprinting, whereas permanent neonatal diabetes is most commonly a defect in the gene encoding the Kir6.2 subunit of the β-cell KATP channel. Diagnosing the latter has implications, since such children can be well managed with sulfonylureas. Point mutations in mitochondrial DNA have been found to be associated with diabetes and deafness The most common mutation occurs at position 3,243 in the tRNA leucine gene, leading to an A-to-G transition. An identical lesion occurs in the MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome); however, diabetes is not part of this syndrome, suggesting different phenotypic expressions of this genetic lesion. Genetic abnormalities that result in the inability to convert proinsulin to insulin have been identified in a few families, and such traits are inherited in an autosomal dominant pattern. The resultant glucose intolerance is mild. Similarly, the production of mutant insulin molecules with resultant impaired receptor binding has also been identified in a few families and is associated with an autosomal inheritance and only mildly impaired or even normal glucose metabolism. Genetic defects in insulin action. There are unusual causes of diabetes that result from genetically determined abnormalities of insulin action. The metabolic abnormalities associated with mutations of the insulin receptor may range from hyperinsulinemia and modest hyperglycemia to severe diabetes. Some individuals with these mutations may have acanthosis nigricans. Women may be virilized and have enlarged, cystic ovaries. In the past, this syndrome was termed type A insulin resistance. Leprechaunism and the Rabson-Mendenhall syndrome are two pediatric syndromes that have mutations in the insulin receptor gene with subsequent alterations in insulin receptor function and extreme insulin resistance. The former has characteristic facial features and is usually fatal in infancy, while the latter is associated with abnormalities of teeth and nails and pineal gland hyperplasia. Alterations in the structure and function of the insulin receptor cannot be demonstrated in patients with insulin-resistant lipoatrophic diabetes. Therefore, it is assumed that the lesion(s) must reside in the postreceptor signal transduction pathways. Diseases of the exocrine pancreas. Any process that diffusely injures the pancreas can cause diabetes. Acquired processes include pancreatitis, trauma, infection, pancreatectomy, and pancreatic carcinoma. With the exception of that caused by cancer, damage to the pancreas must be extensive for diabetes to occur; adrenocarcinomas that involve only a small portion of the pancreas have been associated with diabetes. This implies a mechanism other than simple reduction in β-cell mass. If extensive enough, cystic fibrosis and hemochromatosis will also damage β-cells and impair insulin secretion. Fibrocalculous pancreatopathy may be accompanied by abdominal pain radiating to the back and pancreatic calcifications identified on X-ray examination. Pancreatic fibrosis and calcium stones in the exocrine ducts have been found at autopsy. Endocrinopathies. Several hormones (e.g., growth hormone, cortisol, glucagon, epinephrine) antagonize insulin action. Excess amounts of these hormones (e.g., acromegaly, Cushing's syndrome, glucagonoma, pheochromocytoma, respectively) can cause diabetes. This generally occurs in individuals with preexisting defects in insulin secretion, and hyperglycemia typically resolves when the hormone excess is resolved. Somatostatinomas, and aldosteronoma-induced hypokalemia, can cause diabetes, at least in part, by inhibiting insulin secretion. Hyperglycemia generally resolves after successful removal of the tumor. Drug- or chemical-induced diabetes. Many drugs can impair insulin secretion. These drugs may not cause diabetes by themselves, but they may precipitate diabetes in individuals with insulin resistance. In such cases, the classification is unclear because the sequence or relative importance of β-cell dysfunction and insulin resistance is unknown. Certain toxins such as Vacor (a rat poison) and intravenous pentamidine can permanently destroy pancreatic β-cells. Such drug reactions fortunately are rare. There are also many drugs and hormones that can impair insulin action. Examples include nicotinic acid and glucocorticoids. Patients receiving α-interferon have been reported to develop diabetes associated with islet cell antibodies and, in certain instances, severe insulin deficiency. The list shown in Table 1 is not all-inclusive, but reflects the more commonly recognized drug-, hormone-, or toxin-induced forms of diabetes. Table 1 Etiologic classification of diabetes mellitus Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) Immune mediated Idiopathic Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance) Other specific types Genetic defects of β-cell function MODY 3 (Chromosome 12, HNF-1α) MODY 1 (Chromosome 20, HNF-4α) MODY 2 (Chromosome 7, glucokinase) Other very rare forms of MODY (e.g., MODY 4: Chromosome 13, insulin promoter factor-1; MODY 6: Chromosome 2, NeuroD1; MODY 7: Chromosome 9, carboxyl ester lipase) Transient neonatal diabetes (most commonly ZAC/HYAMI imprinting defect on 6q24) Permanent neonatal diabetes (most commonly KCNJ11 gene encoding Kir6.2 subunit of β-cell KATP channel) Mitochondrial DNA Others Genetic defects in insulin action Type A insulin resistance Leprechaunism Rabson-Mendenhall syndrome Lipoatrophic diabetes Others Diseases of the exocrine pancreas Pancreatitis Trauma/pancreatectomy Neoplasia Cystic fibrosis Hemochromatosis Fibrocalculous pancreatopathy Others Endocrinopathies Acromegaly Cushing's syndrome Glucagonoma Pheochromocytoma Hyperthyroidism Somatostatinoma Aldosteronoma Others Drug or chemical induced Vacor Pentamidine Nicotinic acid Glucocorticoids Thyroid hormone Diazoxide β-Adrenergic agonists Thiazides Dilantin γ-Interferon Others Infections Congenital rubella Cytomegalovirus Others Uncommon forms of immune-mediated diabetes “Stiff-man” syndrome Anti-insulin receptor antibodies Others Other genetic syndromes sometimes associated with diabetes Down syndrome Klinefelter syndrome Turner syndrome Wolfram syndrome Friedreich ataxia Huntington chorea Laurence-Moon-Biedl syndrome Myotonic dystrophy Porphyria Prader-Willi syndrome Others Gestational diabetes mellitus Patients with any form of diabetes may require insulin treatment at some stage of their disease. Such use of insulin does not, of itself, classify the patient. Infections. Certain viruses have been associated with β-cell destruction. Diabetes occurs in patients with congenital rubella, although most of these patients have HLA and immune markers characteristic of type 1 diabetes. In addition, coxsackievirus B, cytomegalovirus, adenovirus, and mumps have been implicated in inducing certain cases of the disease. Uncommon forms of immune-mediated diabetes. In this category, there are two known conditions, and others are likely to occur. The stiff-man syndrome is an autoimmune disorder of the central nervous system characterized by stiffness of the axial muscles with painful spasms. Patients usually have high titers of the GAD autoantibodies, and approximately one-third will develop diabetes. Anti-insulin receptor antibodies can cause diabetes by binding to the insulin receptor, thereby blocking the binding of insulin to its receptor in target tissues. However, in some cases, these antibodies can act as an insulin agonist after binding to the receptor and can thereby cause hypoglycemia. Anti-insulin receptor antibodies are occasionally found in patients with systemic lupus erythematosus and other autoimmune diseases. As in other states of extreme insulin resistance, patients with anti-insulin receptor antibodies often have acanthosis nigricans. In the past, this syndrome was termed type B insulin resistance. Other genetic syndromes sometimes associated with diabetes. Many genetic syndromes are accompanied by an increased incidence of diabetes. These include the chromosomal abnormalities of Down syndrome, Klinefelter syndrome, and Turner syndrome. Wolfram syndrome is an autosomal recessive disorder characterized by insulin-deficient diabetes and the absence of β-cells at autopsy. Additional manifestations include diabetes insipidus, hypogonadism, optic atrophy, and neural deafness. Other syndromes are listed in Table 1. GDM For many years, GDM has been defined as any degree of glucose intolerance with onset or first recognition during pregnancy. Although most cases resolve with delivery, the definition applied whether or not the condition persisted after pregnancy and did not exclude the possibility that unrecognized glucose intolerance may have antedated or begun concomitantly with the pregnancy. This definition facilitated a uniform strategy for detection and classification of GDM, but its limitations were recognized for many years. As the ongoing epidemic of obesity and diabetes has led to more type 2 diabetes in women of childbearing age, the number of pregnant women with undiagnosed type 2 diabetes has increased. After deliberations in 2008–2009, the International Association of Diabetes and Pregnancy Study Groups (IADPSG), an international consensus group with representatives from multiple obstetrical and diabetes organizations, including the American Diabetes Association (ADA), recommended that high-risk women found to have diabetes at their initial prenatal visit, using standard criteria (Table 3), receive a diagnosis of overt, not gestational, diabetes. Approximately 7% of all pregnancies (ranging from 1 to 14%, depending on the population studied and the diagnostic tests employed) are complicated by GDM, resulting in more than 200,000 cases annually. CATEGORIES OF INCREASED RISK FOR DIABETES In 1997 and 2003, the Expert Committee on Diagnosis and Classification of Diabetes Mellitus (1,2) recognized an intermediate group of individuals whose glucose levels do not meet criteria for diabetes, yet are higher than those considered normal. These people were defined as having impaired fasting glucose (IFG) [fasting plasma glucose (FPG) levels 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l)], or impaired glucose tolerance (IGT) [2-h values in the oral glucose tolerance test (OGTT) of 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l)]. Individuals with IFG and/or IGT have been referred to as having prediabetes, indicating the relatively high risk for the future development of diabetes. IFG and IGT should not be viewed as clinical entities in their own right but rather risk factors for diabetes as well as cardiovascular disease. They can be observed as intermediate stages in any of the disease processes listed in Table 1. IFG and IGT are associated with obesity (especially abdominal or visceral obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. Structured lifestyle intervention, aimed at increasing physical activity and producing 5–10% loss of body weight, and certain pharmacological agents have been demonstrated to prevent or delay the development of diabetes in people with IGT; the potential impact of such interventions to reduce mortality or the incidence of cardiovascular disease has not been demonstrated to date. It should be noted that the 2003 ADA Expert Committee report reduced the lower FPG cut point to define IFG from 110 mg/dl (6.1 mmol/l) to 100 mg/dl (5.6 mmol/l), in part to ensure that prevalence of IFG was similar to that of IGT. However, the World Health Organization (WHO) and many other diabetes organizations did not adopt this change in the definition of IFG. As A1C is used more commonly to diagnose diabetes in individuals with risk factors, it will also identify those at higher risk for developing diabetes in the future. When recommending the use of the A1C to diagnose diabetes in its 2009 report, the International Expert Committee (3) stressed the continuum of risk for diabetes with all glycemic measures and did not formally identify an equivalent intermediate category for A1C. The group did note that those with A1C levels above the laboratory “normal” range but below the diagnostic cut point for diabetes (6.0 to <6.5%) are at very high risk of developing diabetes. Indeed, incidence of diabetes in people with A1C levels in this range is more than 10 times that of people with lower levels (4–7). However, the 6.0 to <6.5% range fails to identify a substantial number of patients who have IFG and/or IGT. Prospective studies indicate that people within the A1C range of 5.5–6.0% have a 5-year cumulative incidence of diabetes that ranges from 12 to 25% (4–7), which is appreciably (three- to eightfold) higher than incidence in the U.S. population as a whole (8). Analyses of nationally representative data from the National Health and Nutrition Examination Survey (NHANES) indicate that the A1C value that most accurately identifies people with IFG or IGT falls between 5.5 and 6.0%. In addition, linear regression analyses of these data indicate that among the nondiabetic adult population, an FPG of 110 mg/dl (6.1 mmol/l) corresponds to an A1C of 5.6%, while an FPG of 100 mg/dl (5.6 mmol/l) corresponds to an A1C of 5.4% (R.T. Ackerman, personal communication). Finally, evidence from the Diabetes Prevention Program (DPP), wherein the mean A1C was 5.9% (SD 0.5%), indicates that preventive interventions are effective in groups of people with A1C levels both below and above 5.9% (9). For these reasons, the most appropriate A1C level above which to initiate preventive interventions is likely to be somewhere in the range of 5.5–6%. As was the case with FPG and 2-h PG, defining a lower limit of an intermediate category of A1C is somewhat arbitrary, as the risk of diabetes with any measure or surrogate of glycemia is a continuum, extending well into the normal ranges. To maximize equity and efficiency of preventive interventions, such an A1C cut point should balance the costs of “false negatives” (failing to identify those who are going to develop diabetes) against the costs of “false positives” (falsely identifying and then spending intervention resources on those who were not going to develop diabetes anyway). As is the case with the glucose measures, several prospective studies that used A1C to predict the progression to diabetes demonstrated a strong, continuous association between A1C and subsequent diabetes. In a systematic review of 44,203 individuals from 16 cohort studies with a follow-up interval averaging 5.6 years (range 2.8--12 years), those with an A1C between 5.5 and 6.0% had a substantially increased risk of diabetes with 5-year incidences ranging from 9 to 25%. An A1C range of 6.0--6.5% had a 5-year risk of developing diabetes between 25 and 50% and relative risk 20 times higher compared with an A1C of 5.0% (10). In a community-based study of black and white adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than was fasting glucose (11). Other analyses suggest that an A1C of 5.7% is associated with similar diabetes risk to the high-risk participants in the DPP (12). Hence, it is reasonable to consider an A1C range of 5.7--6.4% as identifying individuals with high risk for future diabetes, to whom the term prediabetes may be applied. Individuals with an A1C of 5.7–6.4% should be informed of their increased risk for diabetes as well as cardiovascular disease and counseled about effective strategies, such as weight loss and physical activity, to lower their risks. As with glucose measurements, the continuum of risk is curvilinear, so that as A1C rises, the risk of diabetes rises disproportionately. Accordingly, interventions should be most intensive and follow-up should be particularly vigilant for those with A1C levels above 6.0%, who should be considered to be at very high risk. However, just as an individual with a fasting glucose of 98 mg/dl (5.4 mmol/l) may not be at negligible risk for diabetes, individuals with A1C levels below 5.7% may still be at risk, depending on level of A1C and presence of other risk factors, such as obesity and family history. Table 2 summarizes the categories of increased risk for diabetes. Evaluation of patients at risk should incorporate a global risk factor assessment for both diabetes and cardiovascular disease. Screening for and counseling about risk of diabetes should always be in the pragmatic context of the patient's comorbidities, life expectancy, personal capacity to engage in lifestyle change, and overall health goals. Table 2 Categories of increased risk for diabetes (prediabetes)* FPG 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l) [IFG] 2-h PG in the 75-g OGTT 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l) [IGT] A1C 5.7–6.4% *For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at higher ends of the range. DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS For decades, the diagnosis of diabetes has been based on glucose criteria, either the FPG or the 75-g OGTT. In 1997, the first Expert Committee on the Diagnosis and Classification of Diabetes Mellitus revised the diagnostic criteria, using the observed association between FPG levels and presence of retinopathy as the key factor with which to identify threshold glucose level. The Committee examined data from three cross-sectional epidemiologic studies that assessed retinopathy with fundus photography or direct ophthalmoscopy and measured glycemia as FPG, 2-h PG, and A1C. These studies demonstrated glycemic levels below which there was little prevalent retinopathy and above which the prevalence of retinopathy increased in an apparently linear fashion. The deciles of the three measures at which retinopathy began to increase were the same for each measure within each population. Moreover, the glycemic values above which retinopathy increased were similar among the populations. These analyses confirmed the long-standing diagnostic 2-h PG value of ≥200 mg/dl (11.1 mmol/l). However, the older FPG diagnostic cut point of 140 mg/dl (7.8 mmol/l) was noted to identify far fewer individuals with diabetes than the 2-h PG cut point. The FPG diagnostic cut point was reduced to ≥126 mg/dl (7.0 mmol/l). A1C is a widely used marker of chronic glycemia, reflecting average blood glucose levels over a 2- to 3-month period of time. The test plays a critical role in the management of the patient with diabetes, since it correlates well with both microvascular and, to a lesser extent, macrovascular complications and is widely used as the standard biomarker for the adequacy of glycemic management. Prior Expert Committees have not recommended use of the A1C for diagnosis of diabetes, in part due to lack of standardization of the assay. However, A1C assays are now highly standardized so that their results can be uniformly applied both temporally and across populations. In their recent report (3), an International Expert Committee, after an extensive review of both established and emerging epidemiological evidence, recommended the use of the A1C test to diagnose diabetes, with a threshold of ≥6.5%, and ADA affirms this decision. The diagnostic A1C cut point of 6.5% is associated with an inflection point for retinopathy prevalence, as are the diagnostic thresholds for FPG and 2-h PG (3). The diagnostic test should be performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial reference assay. Point-of-care A1C assays are not sufficiently accurate at this time to use for diagnostic purposes. There is an inherent logic to using a more chronic versus an acute marker of dysglycemia, particularly since the A1C is already widely familiar to clinicians as a marker of glycemic control. Moreover, the A1C has several advantages to the FPG, including greater convenience, since fasting is not required, evidence to suggest greater preanalytical stability, and less day-to-day perturbations during periods of stress and illness. These advantages, however, must be balanced by greater cost, the limited availability of A1C testing in certain regions of the developing world, and the incomplete correlation between A1C and average glucose in certain individuals. In addition, the A1C can be misleading in patients with certain forms of anemia and hemoglobinopathies, which may also have unique ethnic or geographic distributions. For patients with a hemoglobinopathy but normal red cell turnover, such as sickle cell trait, an A1C assay without interference from abnormal hemoglobins should be used (an updated list is available at http://www.ngsp.org/interf.asp). For conditions with abnormal red cell turnover, such as anemias from hemolysis and iron deficiency, the diagnosis of diabetes must employ glucose criteria exclusively. The established glucose criteria for the diagnosis of diabetes remain valid. These include the FPG and 2-h PG. Additionally, patients with severe hyperglycemia such as those who present with severe classic hyperglycemic symptoms or hyperglycemic crisis can continue to be diagnosed when a random (or casual) plasma glucose of ≥200 mg/dl (11.1 mmol/l) is found. It is likely that in such cases the health care professional would also measure an A1C test as part of the initial assessment of the severity of the diabetes and that it would (in most cases) be above the diagnostic cut point for diabetes. However, in rapidly evolving diabetes, such as the development of type 1 diabetes in some children, A1C may not be significantly elevated despite frank diabetes. Just as there is less than 100% concordance between the FPG and 2-h PG tests, there is not full concordance between A1C and either glucose-based test. Analyses of NHANES data indicate that, assuming universal screening of the undiagnosed, the A1C cut point of ≥6.5% identifies one-third fewer cases of undiagnosed diabetes than a fasting glucose cut point of ≥126 mg/dl (7.0 mmol/l) (www.cdc.gov/diabetes/pubs/factsheet11/tables1_2.htm). However, in practice, a large portion of the population with type 2 diabetes remains unaware of their condition. Thus, it is conceivable that the lower sensitivity of A1C at the designated cut point will be offset by the test's greater practicality, and that wider application of a more convenient test (A1C) may actually increase the number of diagnoses made. Further research is needed to better characterize those patients whose glycemic status might be categorized differently by two different tests (e.g., FPG and A1C), obtained in close temporal approximation. Such discordance may arise from measurement variability, change over time, or because A1C, FPG, and postchallenge glucose each measure different physiological processes. In the setting of an elevated A1C but “nondiabetic” FPG, the likelihood of greater postprandial glucose levels or increased glycation rates for a given degree of hyperglycemia may be present. In the opposite scenario (high FPG yet A1C below the diabetes cut point), augmented hepatic glucose production or reduced glycation rates may be present. As with most diagnostic tests, a test result diagnostic of diabetes should be repeated to rule out laboratory error, unless the diagnosis is clear on clinical grounds, such as a patient with classic symptoms of hyperglycemia or hyperglycemic crisis. It is preferable that the same test be repeated for confirmation, since there will be a greater likelihood of concurrence in this case. For example, if the A1C is 7.0% and a repeat result is 6.8%, the diagnosis of diabetes is confirmed. However, there are scenarios in which results of two different tests (e.g., FPG and A1C) are available for the same patient. In this situation, if the two different tests are both above the diagnostic thresholds, the diagnosis of diabetes is confirmed. On the other hand, when two different tests are available in an individual and the results are discordant, the test whose result is above the diagnostic cut point should be repeated, and the diagnosis is made on the basis of the confirmed test. That is, if a patient meets the diabetes criterion of the A1C (two results ≥6.5%) but not the FPG (<126 mg/dl or 7.0 mmol/l), or vice versa, that person should be considered to have diabetes. Admittedly, in most circumstance the “nondiabetic” test is likely to be in a range very close to the threshold that defines diabetes. Since there is preanalytic and analytic variability of all the tests, it is also possible that when a test whose result was above the diagnostic threshold is repeated, the second value will be below the diagnostic cut point. This is least likely for A1C, somewhat more likely for FPG, and most likely for the 2-h PG. Barring a laboratory error, such patients are likely to have test results near the margins of the threshold for a diagnosis. The healthcare professional might opt to follow the patient closely and repeat the testing in 3–6 months. The decision about which test to use to assess a specific patient for diabetes should be at the discretion of the health care professional, taking into account the availability and practicality of testing an individual patient or groups of patients. Perhaps more important than which diagnostic test is used, is that the testing for diabetes be performed when indicated. There is discouraging evidence indicating that many at-risk patients still do not receive adequate testing and counseling for this increasingly common disease, or for its frequently accompanying cardiovascular risk factors. The current diagnostic criteria for diabetes are summarized in Table 3. Table 3 Criteria for the diagnosis of diabetes Diagnosis of GDM GDM carries risks for the mother and neonate. The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study (13), a large-scale (∼25,000 pregnant women) multinational epidemiologic study, demonstrated that risk of adverse maternal, fetal, and neonatal outcomes continuously increased as a function of maternal glycemia at 24–28 weeks, even within ranges previously considered normal for pregnancy. For most complications, there was no threshold for risk. These results have led to careful reconsideration of the diagnostic criteria for GDM. After deliberations in 2008–2009, the IADPSG, an international consensus group with representatives from multiple obstetrical and diabetes organizations, including ADA, developed revised recommendations for diagnosing GDM. The group recommended that all women not known to have diabetes undergo a 75-g OGTT at 24–28 weeks of gestation. Additionally, the group developed diagnostic cut points for the fasting, 1-h, and 2-h plasma glucose measurements that conveyed an odds ratio for adverse outcomes of at least 1.75 compared with women with mean glucose levels in the HAPO study. Current screening and diagnostic strategies, based on the IADPSG statement (14), are outlined in Table 4. Table 4 Screening for and diagnosis of GDM Perform a 75-g OGTT, with plasma glucose measurement fasting and at 1 and 2 h, at 24–28 weeks of gestation in women not previously diagnosed with overt diabetes. The OGTT should be performed in the morning after an overnight fast of at least 8 h. The diagnosis of GDM is made when any of the following plasma glucose values are exceeded: Fasting: ≥92 mg/dl (5.1 mmol/l) 1 h: ≥180 mg/dl (10.0 mmol/l) 2 h: ≥153 mg/dl (8.5 mmol/l) These new criteria will significantly increase the prevalence of GDM, primarily because only one abnormal value, not two, is sufficient to make the diagnosis. The ADA recognizes the anticipated significant increase in the incidence of GDM to be diagnosed by these criteria and is sensitive to concerns about the “medicalization” of pregnancies previously categorized as normal. These diagnostic criteria changes are being made in the context of worrisome worldwide increases in obesity and diabetes rates, with the intent of optimizing gestational outcomes for women and their babies. Admittedly, there are few data from randomized clinical trials regarding therapeutic interventions in women who will now be diagnosed with GDM based on only one blood glucose value above the specified cut points (in contrast to the older criteria that stipulated at least two abnormal values). Expected benefits to their pregnancies and offspring is inferred from intervention trials that focused on women with more mild hyperglycemia than identified using older GDM diagnostic criteria and that found modest benefits (15,16). The frequency of their follow-up and blood glucose monitoring is not yet clear but likely to be less intensive than women diagnosed by the older criteria. Additional well-designed clinical studies are needed to determine the optimal intensity of monitoring and treatment of women with GDM diagnosed by the new criteria (that would not have met the prior definition of GDM). It is important to note that 80–90% of women in both of the mild GDM studies (whose glucose values overlapped with the thresholds recommended herein) could be managed with lifestyle therapy alone.
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment

            Peritonitis is a common and serious complication of peritoneal dialysis (PD). Although less than 5% of peritonitis episodes result in death, peritonitis is the direct or major contributing cause of death in around 16% of PD patients (1–6). In addition, severe or prolonged peritonitis leads to structural and functional alterations of the peritoneal membrane, eventually leading to membrane failure. Peritonitis is a major cause of PD technique failure and conversion to long-term hemodialysis (1,5,7,8). Recommendations under the auspices of the International Society for Peritoneal Dialysis (ISPD) were first published in 1983 and revised in 1993, 1996, 2000, 2005, and 2010 (9–14). The present recommendations are organized into 5 sections: Peritonitis rate Prevention of peritonitis Initial presentation and management of peritonitis Subsequent management of peritonitis Future research These recommendations are evidence-based where such evidence exists. Publications in or before December 2015 were reviewed. The bibliography is not intended to be comprehensive. When there were many similar publications on the same area, the committee included articles that were recently published. In general, these recommendations follow the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system for classification of the level of evidence and grade of recommendations in clinical guideline reports (15). Within each recommendation, the strength of the recommendation is indicated as Level 1 (We recommend), Level 2 (We suggest), or not graded, and the quality of the supporting evidence is shown as A (high quality), B (moderate quality), C (low quality), or D (very low quality). The recommendations are not meant to be implemented in every situation indiscriminately. Each PD unit should examine its own pattern of infection, causative organisms, and sensitivities, and adapt the protocols according to local conditions as necessary. Although many of the general principles presented here could be applied to pediatric patients, we focus on peritonitis in adult patients. Clinicians who take care of pediatric PD patients should refer to the latest consensus guideline from our pediatric colleagues for detailed treatment regimens and dosages (16). Peritonitis Rate We recommend that every program should monitor, at least on a yearly basis, the incidence of peritonitis (1C). We recommend that the parameters monitored should include the overall peritonitis rate, peritonitis rates of specific organisms, the percentage of patients per year who are peritonitis-free, and the antimicrobial susceptibilities of the infecting organisms (1C). We suggest that peritonitis rate should be standardly reported as number of episodes per patient-year (not graded). We suggest that organism-specific peritonitis rates should be reported as absolute rates, i.e. as number of episodes per year (not graded). As part of a continuous quality improvement (CQI) program, all PD programs should monitor the incidence of peritonitis on a regular basis (17–19). During the computation, only peritonitis episodes that developed from the first day of PD training should be counted, while relapsing episodes should only be counted once. However, it may also be useful to monitor any peritonitis episode that develops after catheter insertion and before PD training is started. Peritonitis episodes that develop while the patient is hospitalized and PD performed by nurses should also be counted. In addition to the overall peritonitis rate, monitoring should include the peritonitis rate of specific organisms and drug susceptibilities of the infecting organisms (20), which may help to design center-specific empirical antibiotic regimens. With this information, interventions can be implemented when peritonitis rates are rising or unacceptably high. There is a substantial variation in the peritonitis rate reported by different countries, as well as a great deal of variation within countries that is not well explained (1,3,14,19,21–26). Nonetheless, the overall peritonitis rate should be no more than 0.5 episodes per year at risk, although the rate achieved depends considerably on the patient population. In some outstanding centers, an overall peritonitis rate as low as 0.18 to 0.20 episode per year has been reported (27,28). All centers should work to continuously improve their peritonitis rates. There are several methods of reporting peritonitis rates (Table 1) (13,29), and expressing as number of patient-month per episode has been commonly used. However, the committee favors reporting peritonitis rates as number of episodes per year as data are presented in a linear scale. Some centers also monitor the incidence of death associated with peritonitis, which is typically defined as death with active peritonitis or within 4 weeks of a peritonitis episode, or any death during hospitalization for a peritonitis episode (6,12,30). TABLE 1 Methods for Reporting Peritonitis Prevention of Peritonitis Exit-site and catheter-tunnel infections are major predisposing factors to PD-related peritonitis (31). Many prevention strategies aim to reduce the incidence of exit-site and catheter-tunnel infections, and clinical trials in this area often report peritonitis rates as a secondary outcome. In this guideline, we focus on the prevention of peritonitis. The prevention of exit-site and catheter-tunnel infections will be covered in a separate guideline. Catheter Placement We recommend that systemic prophylactic antibiotics be administered immediately prior to catheter insertion (1A). Detailed description of the recommended practice of PD catheter insertion has been covered in another ISPD position paper (32). There are 4 randomized, controlled trials on the use of perioperative intravenous (IV) cefuroxime (33), gentamicin (34,35), vancomycin (36), and cefazolin (35,36) as compared to no treatment. Three of them showed that perioperative antibiotic reduces the incidence of early peritonitis (34–36), while 1 that used cefazolin and gentamicin found no benefit (35). Vancomycin and cefazolin were compared head-to-head in 1 study (36), which showed that vancomycin is more effective than cefazolin. The overall benefit of prophylactic perioperative IV antibiotics was confirmed by a systematic review of these 4 trials (37). Although first-generation cephalosporin may be slightly less effective than vancomycin, the former is still commonly used because of the concern regarding vancomycin resistance. Each PD program should determine its own choice of antibiotic for prophylaxis after considering the local spectrum of antibiotic resistance. No data exist on the effectiveness of routine screening and eradication of Staphylococcus aureus nasal carriage before catheter insertion (e.g. by intranasal mupirocin). Besides prophylactic antibiotics, various techniques of catheter placement have been tested. Four randomized trials have compared laparoscopic or peritoneoscopic catheter placement with standard laparotomy (38–41). One study showed that peritoneoscopic insertion led to significantly less early peritonitis (38), but the other 3 were negative (39–41). A systematic review concluded that there is no significant difference in peritonitis rate between these techniques (42). Two studies compared midline with lateral incision (43,44), but neither found any difference in peritonitis rate. Several studies examined the technique of burying the PD catheter in subcutaneous tissue for 4 to 6 weeks after implantation (45–47). The first prospective study with historic control found a decrease in rate of peritonitis (45). In the 2 subsequent randomized studies, one showed a decrease in peritonitis rate with a buried catheter (46), while the other showed no difference (47). One retrospective study found no difference in peritonitis rate between pre-sternal and abdominal swan-neck catheters (48). In summary, there are no convincing data that the buried catheter technique lowers peritonitis rates. Catheter Design The committee has no specific recommendation on catheter design for prevention of peritonitis. There are no convincing data regarding the effect of PD catheter design and configuration on peritonitis risk. Eight randomized trials have compared straight and coiled PD catheters (49–55) and found no difference in peritonitis rate. Two systemic reviews of these trials had the same conclusion (42,56). Two randomized controlled trials found no difference in peritonitis rate between a swan-neck design and the traditional Tenckhoff catheter (57,58). Several retrospective studies suggested that double-cuffed catheters are associated with a lower peritonitis rate than single-cuffed ones (59–62). However, the only randomized trial on this topic showed no difference in peritonitis risk between the two catheter types (63). Downward direction of the tunnel and exit site has theoretical benefits and is often advocated for the prevention of catheter-related peritonitis, but the data supporting this are weak (64). Connection Methods We recommend that disconnect systems with a “flush before fill” design be used for continuous ambulatory PD (CAPD) (1A). For CAPD, several prospective studies confirm that the use of Y connection systems with the “flush before fill” design results in a lower peritonitis rate than the traditional spike systems (65–80). Two systematic reviews concluded that the risk of developing peritonitis was reduced by about one-third with the use of Y systems (42,81). Among all disconnect systems, 1 previous systematic review showed a significantly lower risk of peritonitis with double bag compared with the standard Y systems (82). On the other hand, 2 updated systematic reviews did not find any difference (42,81). It was suggested that the use of conservative statistical techniques might have partly accounted for the lack of difference observed (42). Published studies that compared the peritonitis rate of machine-assisted automated PD (APD) and CAPD showed conflicting results (83–91). However, most of these studies were observational rather than randomized trials, and the analysis of these studies is handicapped by failure to report on the connection type in the cyclers used. At present, the choice of APD versus CAPD should not be based on the risk of peritonitis. Training Programs We recommend that the latest ISPD recommendations for teaching PD patients and their caregivers be followed (92). We recommend that PD training be conducted by nursing staff with the appropriate qualifications and experience (1C). The method of training has an important influence on the risk of PD infections (92–103). Much research is needed on the best approach to train patients on the technique of PD to minimize PD-related infections. Unfortunately, high-level evidence guiding how, where, when, and by whom PD training should be performed is lacking (103). Detailed description of the recommended practice of PD training has been covered in another ISPD guideline (92,93), which each PD program should consult while preparing the trainer and developing a specific curriculum for PD training. In essence, all PD training nurses should receive adequate education to perform training and subsequent further education to update and hone their teaching skills. Each program should have an established curriculum that is followed in teaching the patient the procedure and theory of PD. Testing the patient practical skills at the end of training is essential. After PD training is completed and patients are started on home PD, a home visit by the PD nurse is often useful in detecting problems with exchange technique, adherence to protocols, and other environmental and behavior issues which increase the risk of peritonitis (104–109). However, the effect of home visits on peritonitis risk has not been tested in a prospective study. One retrospective observational study in 22 pediatric patients reported a non-significant reduction in peritonitis rates following the introduction of home visits (110). In addition to the initial training, retraining plays an important role in reducing mistakes according to learning specialists (98,100). Previous studies showed that compliance with exchange protocols was significantly associated with peritonitis rate (98,111). Another study found that 6 months after the initiation of PD, most patients took shortcuts, modified the standard exchange method, or did not follow aseptic technique (102). Re-training may reduce peritonitis risk but data are limited to 2 small-scale uncontrolled studies (98,101). A randomized controlled trial has been completed on re-training and the results are pending (112). The indication, optimal time, and content of retraining have not been well defined. Home visits by PD nurses may be a good way to determine which patients require re-training (98). Other indications for re-training are listed in Table 2 (14,92). Certainly, all patients must be re-trained whenever the equipment to perform PD is changed. TABLE 2 Indications for PD Re-Training Dialysis Solution The committee has no specific recommendation on the choice of dialysis solution for prevention of peritonitis. Early data suggested that the choice of PD solution may affect peritonitis rates, although the results of published trials are conflicting (113–120). The largest and methodologically most robust randomized trial of neutral-pH, low-glucose-degradation-product (GDP) PD solutions demonstrated that these fluids significantly reduced the occurrence and severity of peritonitis compared with conventional solutions (117,121). A subsequent meta-analysis of 6 randomized controlled trials concluded that the quality of many trials was poor and that trial heterogeneity was high (primarily due to risk of attrition bias), such that the use of neutral-pH PD solutions with reduced GDPs had an uncertain effect on the rate of peritonitis (122). The choice of PD solution should therefore currently not be based on the risk of peritonitis. Exit-Site Care We recommend daily topical application of antibiotic (mupirocin or gentamicin) cream or ointment to the catheter exit site (1B). We recommend prompt treatment of exit-site or catheter tunnel infection to reduce subsequent peritonitis risk (1C). General measures concerning exit-site care and meticulous hand hygiene during the dialysis exchange have been recommended and should be emphasized during patient training (14). Wearing a face mask during dialysis exchange is optional. A systematic review of 3 trials found that topical disinfection of the exit site with povidone-iodine did not reduce the risk of peritonitis compared to simple soap and water cleansing or no treatment (123). A number of observational studies, randomized controlled trials, and meta-analyses confirm that prophylaxis with daily application of mupirocin cream or ointment to the skin around the exit site is effective in reducing S. aureus exit-site infection (ESI) and possibly peritonitis (37,42,124–131). This strategy is further shown in another study to be cost-effective (132). In a meta-analysis of 14 studies (only 3 of which were randomized whilst the remaining 11 were historical cohort studies), topical mupirocin reduced the overall risk of S. aureus infection by 72%, and S. aureus peritonitis by 40% (127). One retrospective study showed that once weekly topical mupirocin was less effective than more frequent administration (133). A previous prospective study showed that intranasal mupirocin reduced S. aureus ESI but not peritonitis (134), but this study has been criticized for excluding patients at highest risk for S. aureus PD-related infections. Intranasal mupirocin treatment is also less well accepted by patients (135). A recent study in pediatric patients suggested that the addition of sodium hypochlorite solution to topical mupirocin may further reduce the rate of peritonitis (136). Mupirocin resistance has been reported, particularly with intermittent use but not daily use (137–140). The long-term implication of mupirocin resistance, however, has not been studied in detail. With the extensive use of prophylactic agents against S. aureus infections, Pseudomonas species have become a proportionally more common cause of catheter infection (141). A randomized controlled trial showed that daily application of gentamicin cream to the exit site was highly effective in reducing ESIs caused by Pseudomonas species, and was as effective as topical mupirocin in reducing S. aureus ESIs (125). However, 2 subsequent prospective studies found no significant difference in the rates of infection between patients treated with topical gentamicin and mupirocin ointment (126,142). Other observational studies suggested that the change of prophylactic topical antibiotic protocol from mupirocin to gentamicin cream was associated with an increase in ESI caused by Enterobacteriaceae, Pseudomonas species, and probably non-tuberculous mycobacteria (143,144). At present, topical gentamicin should be considered as an acceptable alternative to mupirocin for prophylactic application at the exit site. Unfortunately, the incidence and implications of gentamicin resistance are uncertain. Other alternative topical antibacterial agents have been tested. A randomized controlled trial found that with standard exit-site care, the rates of catheter infection and peritonitis were similar between patients receiving daily topical application of antibacterial honey to catheter exit site and those treated with intranasal mupirocin ointment (145). Similarly, another randomized trial found that topical triple ointment (polymyxin, bacitracin, and neomycin) was not superior to topical mupirocin in the prophylaxis of PD-related infections (146). Other prophylactic strategies have been tested. In a randomized controlled trial, peritonitis caused by S. aureus or P. aeruginosa ESI was markedly reduced with the use of ciprofloxacin otologic solution to the exit site, as compared to simple soap and water cleansing only (147). Two randomized studies comparing oral rifampicin with no treatment both demonstrated significant reductions in peritonitis risk with rifampicin treatment (148,149). In another study, cyclic oral rifampicin and daily topical mupirocin to the exit site were equally effective in reducing the rate of S. aureus peritonitis (125). However, adverse effects of rifampicin were more common than those of topical mupirocin (124). Moreover, drug interactions involving rifampicin were a real concern, and rifampicin resistance developed in up to 18% of cases with repeated usage (150). The use of oral rifampicin for prophylactic purpose is therefore not routinely advocated. Other oral antibiotics, such as trimethoprim/sulfamethoxazole, cephalexin, and ofloxacin were not effective in reducing peritonitis rates (151–153). There is a strong association between ESI and subsequent peritonitis (31,154,155). Early detection of ESI and prompt management with appropriate antibiotics are logical steps to minimize the risk of subsequent peritonitis (31,154). Bowel and Gynecological Source Infections We suggest antibiotic prophylaxis prior to colonoscopy (2C) and invasive gynecologic procedures (2D). Peritoneal dialysis peritonitis commonly follows invasive interventional procedures (e.g. colonoscopy, hysteroscopy, cholecystectomy) in PD patients (156–160). In a single-center study of 97 colonoscopies performed in 77 CAPD patients, peritonitis occurred in 5 (6.3%) of 79 colonoscopies performed without antibiotic prophylaxis and none of 18 colonoscopies performed with antibiotic prophylaxis (p = 0.58) (157). Another small retrospective observational study reported that prophylactic antibiotics before most endoscopic interventions, colonoscopy, sigmoidoscopy, cystoscopy, hysteroscopy, and hysteroscopy-assisted intrauterine device implantation or removal, but not upper gastrointestinal endoscopy, were associated with a lower peritonitis rate (0/16 vs 7/23, p 100/μL or > 0.1 × 109/L (after a dwell time of at least 2 hours), with > 50% polymorphonuclear; and (3) positive dialysis effluent culture (1C). We recommend that PD patients presenting with cloudy effluent be presumed to have peritonitis and treated as such until the diagnosis can be confirmed or excluded (1C). We recommend that PD effluent be tested for cell count, differential, Gram stain, and culture whenever peritonitis is suspected (1C). Patients with peritonitis usually present with cloudy PD effluent and abdominal pain. Cloudy effluent almost always represents infectious peritonitis, although there are other differential diagnoses (Table 4) (206). Some patients present with cloudy effluent but no or minimal abdominal pain. On the other hand, peritonitis should also be included in the differential diagnosis of the PD patient presenting with abdominal pain, even if the effluent is clear. In addition to the presenting symptoms, the patient should be questioned about any recent contamination, accidental disconnection, endoscopic or gynecologic procedure, as well as the presence of constipation or diarrhea. In addition, the patient should be questioned about past history of peritonitis and ESI. TABLE 4 Differential Diagnosis of Cloudy Effluent On physical examination, abdominal tenderness is typically generalized and is occasionally associated with rebound. Localized pain or tenderness should raise the suspicion of an underlying surgical pathology. Physical examination should also include a careful inspection of the catheter tunnel and exit site. Any discharge from the exit site should be cultured. The degree of abdominal pain and tenderness are important factors in deciding whether a patient requires hospital admission. In general, patients with minimal pain could be treated on an outpatient basis with intraperitoneal (IP) antibiotic therapy if this can be arranged. Follow-up within 3 days is advisable to confirm resolution and appropriateness of the antibiotic choice. When peritonitis is suspected, dialysis effluent should be drained, carefully inspected, and sent for cell count with differential, Gram stain, and culture (207). An effluent cell count with white blood cells (WBC) > 100/μL (after a dwell time of at least 2 hours), with > 50% PMN, is highly suggestive of peritonitis (208). Abdominal X ray is generally not necessary. Peripheral blood culture is usually not necessary but should be obtained if the patient is clinically septic. To prevent delay in treatment, antibiotic therapy (see below) should be initiated once the appropriate dialysis effluent specimens have been collected, without waiting for the results of laboratory testing. The WBC count in the effluent depends in part on the length of the dwell. For patients on APD with rapid cycle treatment, the clinician should use the percentage of PMN rather than the absolute WBC count to diagnose peritonitis, and a proportion above 50% PMN is strong evidence of peritonitis, even if the absolute WBC count is less than 100/μL (208). On the other hand, APD patients without a daytime exchange who present with abdominal pain during the daytime may have no effluent to drain. In this case, 1 L of dialysis solution should be infused, dwelled for 1 to 2 hours, and then drained for inspection and laboratory testing. Some PD patients live far away from medical facilities and cannot be seen expeditiously after the onset of symptoms. Since prompt initiation of therapy for peritonitis is critical, this necessitates reliance on immediate patient reporting of symptoms to the center, and then initiating IP antibiotics in the home setting. Such an approach requires that the patients be trained in this technique and that antibiotics be kept at home. Whenever possible, cultures should be obtained either at a local facility or by having blood culture bottles kept at home for use. However, it is important that no one accesses the PD catheter without the appropriate training or equipment, which is often the case in smaller emergency departments. In this case the patient can drain his/her abdomen and provide the cloudy effluent for culture. Alternatively, the patient may place the cloudy effluent bag in the refrigerator until they can bring the sample to their PD center. The benefit of self-initiated treatment, however, should be carefully balanced against the potential problems of over-diagnosis and habitual misuse of antibiotics. Identification of Causative Organism We recommend that the blood-culture bottle be the preferred technique for bacterial culture of PD effluent (1C). We suggest that sampling and culture methods be reviewed and improved if more than 15% of peritonitis episodes are culture-negative (2C). Gram stain of the PD effluent should be performed even though the result is often negative (209). The yield on the Gram stain is increased if it is performed on centrifuged specimens. An appropriate method of culturing PD effluent is the most important step in establishing the causative organism. In some specialized centers, one could achieve less than 10% rate of culture negative peritonitis. Identification of the organism and subsequent antibiotic sensitivities help to guide the choice of antibiotic, and the type of organism often indicates the possible source of infection. Bedside inoculation of 5 – 10 mL effluent in 2 (aerobic and anaerobic) blood-culture bottles has a reasonable sensitivity, and the culture-negative rate is typically around 10 – 20%. (210,211). The yield of peritoneal fluid culture is enhanced by inoculating the fluid directly into rapid blood-culture bottle kits (e.g. BACTEC, Kent, UK; Septi-Chek, Roche Diagnostics, Basel, Switzerland; BacT/Alert, Biomerieux, Inc., Basingstoke, UK), centrifuging PD fluid and culturing the pellet, or the lysis centrifugation technique compared to inoculation into standard blood-culture bottles. Specifically, centrifugation of 50 mL PD effluent at 3,000 g for 15 minutes, followed by resuspension of the sediment in 3 – 5 mL supernatant and inoculation on solid culture media or standard blood-culture media, increases the yield by 5 to 10 times but is more cumbersome (212,213). The combination of water lysis, Tween-80 blood agar and Triton-X treatment of the PD effluent is also a sensitive culture method (214). The specimens should arrive at the laboratory within 6 hours. If immediate delivery to the laboratory is not possible, the inoculated culture bottles should ideally be incubated at 37°C. The solid media should be incubated in aerobic, microaerophilic, and anaerobic environments. The speed with which bacteriological diagnosis can be established is very important. Concentration methods do not only facilitate microbial identification, but also reduce the time needed for a positive culture. In over 75% of cases, microbiologic diagnosis can be established in less than 3 days. When the causative microorganism has been identified, subsequent cultures for monitoring may be performed by only inoculating the effluent in blood-culture bottles. When cultures remain negative after 3 – 5 days of incubation, PD effluent should be sent for repeat cell count, differential count, fungal, and mycobacterial culture. In addition, subculture on media with aerobic, anaerobic, and microaerophilic incubation conditions for a further 3 – 4 days may help to identify slow-growing fastidious bacteria and yeasts that are undetectable in some automated culture systems. Other Novel Diagnostic Techniques We suggest that there is insufficient evidence to currently support the use of novel techniques for the diagnosis of peritonitis (2D). A number of novel diagnostic techniques have been explored for the early diagnosis of peritonitis, including leukocyte esterase reagent strips, biomarker assays (matrix metalloproteinase-8 and -9, neutrophil gelatinase-associated lipocalin and procalcitonin), polymerase chain reaction (PCR) for bacterial-derived DNA fragments, 16S rRNA gene sequencing, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF), and pathogen-specific “immune fingerprints” (215–226). However, none of them has been proved to be superior to conventional techniques. Other novel techniques have also been developed for rapid species identification and the determination of resistant organisms (e.g. methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci, Klebsiella pneumoniae carbapenemase), which may allow more rapid initiation of focused antimicrobial therapy of resistant pathogens, but their role in the management of PD-related peritonitis remain unclear. Further studies in this area are necessary. Empiric Antibiotic Selection We recommend that empirical antibiotic therapy be initiated as soon as possible after appropriate microbiological specimens have been obtained (1C). We recommend that empirical antibiotic regimens be center-specific and cover both gram-positive and gram-negative organisms (1C). We recommend that gram-positive organisms be covered by vancomycin or a first generation cephalosporin and gram-negative organisms by a third-generation cephalosporin or an aminoglycoside (1B). Antibiotic treatment should aim for rapid resolution of inflammation and preservation of the peritoneal membrane function. No antibiotic regimen has been proved to be superior to others as empirical treatment (203), although the combination of a glycopeptide (vancomycin or teicoplanin) plus ceftazidime was considered to be superior to other regimens in a proportional meta-analysis (227). For gram-positive coverage, several studies compared a first-generation cephalosporin with a glycopeptide-based regimen (228–231). When analyzed as a whole, glycopeptide-based regimens result in a higher complete cure rate, but there is no difference in the rate of primary treatment failure, relapse, or catheter removal (203). A systematic review noted that the result was largely influenced by 1 study, in which the dosage of cefazolin was substantially lower than current recommendations (228). Other studies found no difference in cure rates for vancomycin and cefazolin when an appropriate cephalosporin dose was used (228,230,231). Nonetheless, some PD units have a high rate of methicillin-resistant organisms and vancomycin may be preferable for empirical gram-positive coverage (232), although it remains controversial what threshold prevalence of methicillin resistance would justify the routine empirical use of vancomycin as gram-positive coverage. For the coverage of gram-negative organisms, previous studies have shown that aminoglycosides (e.g. gentamicin or netilmicin) (233), ceftazidime (233), cefepime (234), or a carbapenem (235,236) are all effective. Cefepime per se has reasonable activity against gram-positive bacteria and monotherapy may be feasible (234). Fluoroquinolones could also be used if supported by the local antimicrobial susceptibilities of antibiotic sensitivities (237–241). For patients allergic to cephalosporins, aztreonam is also a possible alternative (242–244). In a randomized controlled study, IP netilmicin and ceftazidime had similar efficacy to empirical gram-negative coverage (233). Short-term aminoglycoside treatment is inexpensive, safe, and provides good gram-negative coverage. There is no evidence that short courses of aminoglycosides accelerate the loss of residual renal function (233,245–247). However, repeated or prolonged aminoglycoside treatment (more than 3 weeks) was associated with a high incidence of vestibular toxicity or oto-toxicity and should be avoided (248,249). In addition to the above combinations, a variety of regimens have been shown by prospective trials to have acceptable results (250). For example, imipenem/cilastatin monotherapy was as effective as cefazolin plus ceftazidime (236), and cefepime was as effective as vancomycin plus netilmicin (234). In another study, oral ofloxacin alone was not inferior to cephalothin plus tobramycin (241), but the effectiveness of ciprofloxacin monotherapy has declined markedly in the past decade (251). It is important to note that antibiotic resistance may develop with extensive empiric use of broad-spectrum cephalosporins or fluoroquinolones. The prevalence of resistant pathogens in each program should be regularly monitored and the choice of empirical antibiotic may need to be changed accordingly. Dosage of Antibiotics We recommend that IP antibiotics be the preferred route of administration unless the patient has features of systemic sepsis (1B). We suggest that IP aminoglycoside be administered as daily intermittent dosing (2B). We recommend that prolonged courses of IP aminoglycoside be avoided (1C). We suggest that IP vancomycin be administered intermittently and the serum vancomycin level be kept above 15 μg/mL (2C). We suggest that IP cephalosporin be administered either continuously (in each exchange) or on a daily intermittent basis (2C). The recommended dosage of antibiotics for the treatment of PD-related peritonitis is summarized in Tables 5 and 6 (236–239,252–303). However, the recommended dosages of many antibiotics are based on published clinical experience rather than formal pharmacokinetic studies. It was recommended previously that for patients with substantial residual renal function, the dose of antibiotics that have renal excretion needs to be adjusted (12,13). However, recent studies suggest that such adjustments are not necessary (284,304). TABLE 5 Intraperitoneal Antibiotic Dosing Recommendations for Treatment of Peritonitis TABLE 6 Systemic Antibiotic Dosing Recommendations for Treatment of Peritonitis In general, IP dosing results in high IP drug levels and is preferable to IV administration. Moreover, IP dosing avoids venipuncture and could be done by the patient at home after appropriate training. Although IV vancomycin is reasonably successful as empirical gram-positive coverage (237), previous studies have shown that IV vancomycin resulted in a significantly higher rate of primary treatment failure than IP administration (203,305). Intraperitoneal antibiotics should be added using sterile technique, such as placing povidone iodine, rubbing with alcohol 70% strip, or chlorhexidine on the medication port for 5 minutes prior to insertion of the needle through the port. Intraperitoneal antibiotics can be given as continuous (i.e. in each exchange) or intermittent dosing (i.e. once daily) (306–310). In intermittent dosing, the antibiotic-containing dialysis solution must be allowed to dwell for at least 6 hours to allow adequate absorption. Many antibiotics have significantly enhanced absorption during peritonitis, which permits reentry into the peritoneal cavity during subsequent PD cycles. For vancomycin, about 50% of IP dosing is absorbed when there is no peritonitis, but nearly 90% in the presence of peritonitis (304,306). A randomized controlled trial in children found that intermittent dosing of vancomycin is as efficacious as continuous dosing (311). The role of monitoring serum vancomycin levels is controversial (284,312). In general, a dosing interval of every 4 to 5 days would keep serum trough levels above 15 μg/mL, but there is substantial inter-individual variability (284,304). Re-dosing is probably appropriate when serum vancomycin levels are below 15 μg/mL (304,313,314). At the dosage currently recommended, the peak gentamicin concentration in dialysis solution is at least 8 times the minimal inhibitory concentration (MIC) of the likely pathogens (315). Two studies showed that once-daily gentamicin is as effective as continuous dosing for CAPD patients (256,316). However, systemic absorption of intermittent IP gentamicin is highly variable and depends on the peritoneal transport characteristics (315), and the high systemic absorption of gentamicin in patients with peritonitis and prolonged plasma elimination half-life may lead to systemic accumulation and subsequent toxicity (315). At the currently recommended dosing regimen, serum gentamicin levels might be excessive in over 50% of patients (304), and higher serum levels were not associated with better cure rates (304). However, there is no firm evidence that monitoring aminoglycoside levels mitigates toxicity risk or enhances efficacy (314). The serum gentamicin level on day 2 is not associated with treatment efficacy or adverse effects during short-course therapy (317). Studies on the relationship between serum aminoglycoside levels following IP administration and the subsequent risk of ototoxicity are conflicting and often show a negative result (318-321). Taken together, serum aminoglycoside level monitoring for PD patients receiving IP treatment seems to play a small role. Once the causative bacteria are identified and sensitivity confirmed, early switch from empirical aminoglycoside to other agents (e.g. third-generation cephalosporin) could minimize the risk of ototoxicity (314). For cephalosporins, there are few data on whether continuous dosing is more efficacious than intermittent dosing. In CAPD patients, IP cefazolin 500 mg/L once daily results in acceptable 24-hour levels in the PD fluid (308). Although continuous IP ceftazidime is traditionally given at the same dose as cefazolin (13), once-daily IP ceftazidime at a dose of 20 mg/kg once daily may not provide adequately therapeutic levels in dialysis solution throughout 24 hours (267). One pharmacokinetic study showed that a loading dose of 3 g is necessary to achieve an adequate dialysis solution drug concentration (322), which could be followed by maintenance IP dosing of 1 gm q24h or 2 gm q48h (322). Oral administration of fluoroquinolones is commonly used alone or in combination with other antibiotics (237). Oral ciprofloxacin and moxifloxacin reach adequate levels within the peritoneum (293,323). However, adequate IP levels may require a day to be reached, and some oral phosphate binders can bind fluoroquinolones and reduce their bioavailability (324,325). Ciprofloxacin is effective against Pseudomonas species, while moxifloxacin has better coverage of gram-positive organisms. A systematic review of 2 low-quality studies concluded that IP fluoroquinolone may achieve better complete cure rate than oral treatment, although failure rates were high in both arms of these studies (203,276,279). Antibiotic Delivery and Stability The stability and compatibility of various antibiotics for IP administration was reviewed previously (326). In essence, vancomycin, aminoglycosides, and cephalosporins can be mixed in the same dialysis solution bag without loss of bioactivity. Aminoglycosides and cephalosporins can be added to the same bag, although aminoglycoside should not be added to the same bag with penicillins because of chemical incompatibility (326). For any antibiotics that are to be admixed, separate syringes must be used for adding the antibiotics. Although vancomycin and ceftazidime are compatible when added to dialysis solutions (1 L total volume or greater), they are incompatible if combined in the same syringe or added to an empty dialysis solution bag for reinfusion into the patient. Antibiotics are stable for variable times after being added to the PD solution (327). Vancomycin is stable for 28 days in dialysis solutions stored at room temperature, although higher ambient temperatures will reduce the duration of stability. Gentamicin is stable for 14 days both at room temperature and under refrigeration, but the duration of stability is reduced by admixture with heparin. Cefazolin is stable for 8 days at room temperature or for 14 days if refrigerated; addition of heparin has no adverse influence. Ceftazidime is stable for 4 days at room temperature or 7 days if refrigerated. Cefepime is stable for 14 days if the solution is refrigerated (328). Data on the stability of various new antibiotics and PD solutions are limited and often fragmented (329–332). Clinicians should remain alert for new studies in this area. In general, icodextrin-based PD solutions are compatible with vancomycin, cefazolin, ceftazidime, and gentamicin (329,333,334). When premixed in icodextrin solution, these antibiotics are least stable at 37°C and most stable at 4°C, permitting storage for 14 days when refrigerated and pre-warming to body temperature prior to administration (334). Special Considerations for APD There is a substantial knowledge gap regarding the antibiotic dosing requirements for the treatment of peritonitis in APD patients. In general, the intermittent IP dosing listed in Table 4 could be given in the day dwell of APD patients. However, extrapolation of data from CAPD to APD may result in significant under-dosing in APD patients because rapid exchanges in APD may lead to inadequate time to achieve therapeutic levels when antibiotics are given IP intermittently, and APD results in a higher peritoneal clearance of antibiotics than CAPD. This problem is particularly obvious amongst high peritoneal transporters. Alternatively, APD patients who develop peritonitis may switch temporarily to CAPD. However, it is not always practical to switch because patients may not be familiar with the exchange technique, and the supplies for CAPD may not be immediately available. A recent report also found that this practice is associated with an increased risk of technique failure and fluid overload (335). Resetting the cycler to permit a longer exchange time in such cases is a logical alternative, but the efficacy of this approach has not been well studied. For patients who remain on rapid-cycle APD, there are few data concerning efficacy of first-generation cephalosporins given intermittently. For APD patients treated with cephalosporins added to the daytime exchange only, the nighttime IP levels are below the MIC of most organisms. Adding first-generation cephalosporin to each exchange would appear to be the safest approach. Although the IP vancomycin level may be low in APD patients due to slow diffusion from blood to dialysis solution, a randomized controlled trial in children showed that intermittent dosing of vancomycin was as effective as continuous dosing in children receiving APD (311). Vancomycin can probably be given intermittently for APD patients. Oral ciprofloxacin can also achieve adequate levels within the peritoneum in APD patients (323). In a retrospective, single-center observational cohort study of 508 episodes of PD-associated peritonitis in 208 patients, no differences in relapse rates, mortality, or the combined end-point of mortality and catheter removal were observed between APD and CAPD patients continuing their own PD modality during continuous IP antibiotic treatment in each PD exchange, although elevated dialysis effluent leukocyte counts and antibiotic treatment durations were longer in the former (90). Adjunctive Treatments Some patients with PD-related peritonitis could be managed on an outpatient basis. The decision to hospitalize a patient depends on many factors, including hemodynamic status of the patient, severity of signs and symptoms, and, for APD patients, the type of treatment schedule chosen, as well as the ability to provide IP antibiotics as an outpatient and the reliability of the patient. The rationale for anti-fungal prophylaxis has been discussed in a previous section (see Secondary Prevention, above). Patients with cloudy effluent may benefit from the addition of heparin 500 units/L IP to prevent occlusion of the catheter by fibrin. Depending on the severity of symptoms, some patients would require analgesics for pain control. At the initial presentation and before IP antibiotics are initiated, 1 or 2 rapid PD exchanges are often performed for pain relief, although there are no data supporting this approach. A randomized controlled trial showed that more extensive rapid-cycle peritoneal lavage during the first 24 hours of peritonitis did not affect the rate of complete cure or relapse as compared to the usual practice of 2 rapid exchange cycles (336). Intraperitoneal urokinase has been advocated for the treatment of biofilm, which may be the cause of refractory or relapsing peritonitis. A retrospective study found that IP urokinase and oral rifampicin, in addition to conventional antibiotics, resulted in catheter salvage in 64% of cases with persisting asymptomatic infection following coagulase-negative staphylococcus peritonitis (337). Randomized controlled trials, however, failed to show any benefit of IP urokinase for the treatment of refractory peritonitis (338–340). The rates of complete cure, catheter removal, or relapsing episode, as well as overall mortality were not affected by adjunctive treatment with IP urokinase. In contrast, 1 randomized controlled study showed that simultaneous catheter removal and replacement was superior to IP urokinase in reducing relapsing peritonitis episodes (341). Peritoneal permeability to water, glucose, and proteins typically increases during peritonitis. Reduction in ultrafiltration is commonly observed, and fluid overload is a frequent complication. Temporary use of hypertonic exchanges and short dwell times may be needed to maintain adequate fluid removal. Temporary use of icodextrin solution may prevent fluid overload in PD patients with acute peritonitis (342). Because of rapid glucose absorption, glycemic control may worsen in diabetic patients. Blood glucose monitoring with appropriate adjustments of insulin dosage may be needed. Protein loss during peritonitis is also increased. Screening for malnutrition should be undertaken in patients with prolonged peritoneal inflammation. Subsequent Management of Peritonitis We recommend that antibiotic therapy be adjusted to narrow-spectrum agents, as appropriate, once culture results and sensitivities are known. (1C). The management algorithms for gram-positive cocci and gram-negative bacilli identified in dialysis effluent are summarized in Figures 2 and 3, respectively. Within 48 hours of initiating therapy, most patients with PD-related peritonitis will show considerable clinical improvement. The effluent should be visually inspected regularly to determine whether clearing is occurring. If there is no improvement after 48 hours, cell counts and repeat cultures should be performed. In addition, monitoring of WBC count in PD effluent may predict treatment response. A retrospective study showed that dialysis effluent WBC count ≥ 1,090/mm3 on day 3 was an independent prognostic marker for treatment failure (343). Figure 2 — Management algorithm for gram-positive cocci identified in dialysis effluent. Figure 3 — Management algorithm for gram-negative bacilli or mixed bacterial growth identified in dialysis effluent. * Trimethoprim/sulfamethoxazole is preferred for Stenotrophomonas species. Refractory Peritonitis We recommend that the PD catheter be removed promptly in refractory peritonitis episodes, defined as failure of the PD effluent to clear up after 5 days of appropriate antibiotics (1C). After initiation of antibiotic treatment, there is usually clinical improvement in 72 hours. Refractory peritonitis is defined as failure of the PD effluent to clear up after 5 days of appropriate antibiotics (Table 7). Catheter removal is indicated in case of refractory peritonitis, or earlier if the patient's clinical condition is deteriorating, in order to preserve the peritoneum for future PD as well as preventing morbidity and mortality. Prolonged attempts to treat refractory peritonitis by antibiotics without catheter removal are associated with extended hospital stay, peritoneal membrane damage, increased risk of fungal peritonitis, and excessive mortality (344). TABLE 7 Terminology for Peritonitis Relapsing, Recurrent, and Repeat Peritonitis We recommend that timely catheter removal be considered for relapsing, recurrent, or repeat peritonitis episodes (1C). The definitions of relapsing, recurrent, and repeat peritonitis are summarized in Table 7. Retrospective studies showed that relapsing, recurrent, and repeat peritonitis episodes are caused by different species of bacteria and probably represent distinct clinical entities (166,345–347). When compared to non-relapsing episodes, relapsing ones are associated with a lower rate of cure, more ultrafiltration problems, and higher rate of technique failure (166,348). Recurrent peritonitis episodes had a worse prognosis than relapsing ones (166,345). A recent study suggested that bacterial DNA fragment levels in PD effluent are significantly higher 5 days before and on the date of completion of antibiotics amongst patients who subsequently develop relapsing or recurrent peritonitis (349). Another study suggests that effluent white cell count and leukocyte strip test at the time of stopping antibiotics may also predict relapse (350). However, further studies are needed to validate these results and confirm their clinical utility. Coagulase-Negative Staphylococcus We suggest that coagulase-negative staphylococci generally be treated with IP cephalosporins or vancomycin, according to antimicrobial susceptibility, for a period of 2 weeks. (2C). Coagulase-negative Staphylococcus peritonitis episodes, especially those caused by S. epidermidis, are mostly due to touch contamination. Many patients with S. epidermidis peritonitis have mild clinical symptoms and respond well to treatment as outpatients (351–353). In some centers, the prevalence of methicillin resistance is now very high (354,355), and vancomycin may have to be considered as empirical therapy. Even for methicillin-sensitive strains, it is important to avoid inadequate IP antibiotic levels, which may lead to relapsing peritonitis. For this reason, continuous dosing of IP first-generation cephalosporins is preferable to intermittent dosing. Effective antibiotic treatment for 2 weeks is generally sufficient (351–354). The patient's exchange technique should be reviewed to prevent another episode. Relapsing coagulase-negative Staphylococcus peritonitis suggests colonization of the PD catheter with biofilm, and catheter removal should be considered. When the PD effluent becomes clear with antibiotic therapy, many of these patients could have simultaneous re-insertion of a new catheter as a single procedure under antibiotic coverage, and temporary hemodialysis could be avoided (204). In addition to conventional antibiotics, a retrospective study found that IP urokinase and oral rifampicin resulted in catheter salvage in 64% of cases with persisting asymptomatic infection following coagulase-negative Staphylococcus peritonitis (337), but the benefit of this approach needs to be confirmed by further studies. Enterococcus Species We suggest that enterococcal peritonitis be treated for 3 weeks with IP vancomycin (2C). We suggest adding IP aminoglycoside for severe enterococcal peritonitis (2D). For peritonitis due to vancomycin-resistant Enterococcus (VRE), we suggest treatment for 3 weeks with IP ampicillin if the organism is susceptible or with alternative antibiotics (linezolid, quinupristin/dalfopristin, daptomycin or teicoplanin, based on antimicrobial susceptibilities) if the organism is ampicillin-resistant (2D). Enterococci are normal flora of the gastrointestinal tract (356,357). Intra-abdominal source must be considered. Other pathogenic organisms are isolated in about half of the cases of enterococcal peritonitis, and the coexistence of other organisms was associated with high rates of catheter removal, permanent hemodialysis transfer, and death (356,357). Enterococcal species are always resistant to cephalosporins. Identification of the exact species is important because resistance to penicillins and carbapenems is far more frequently observed in E. faecium than in E. faecalis (358). Although there may be clinical response to empirical therapy with first-generation cephalosporins (359), peritonitis episodes should be treated with IP vancomycin if the organism is susceptible. For patients with severe signs or symptoms, an aminoglycoside may be added for synergy. However, aminoglycosides should not be added to the same bag with penicillins because of chemical incompatibility (see Antibiotic Delivery and Stability). Although ampicillin has little in vitro activity when added to common PD solutions (331), clinical experience suggests clinical efficiency (356). For vancomycin-resistant enterococcus (VRE) causing peritonitis, if the bacterial isolate is ampicillin-susceptible, ampicillin remains the drug of choice. Otherwise, linezolid, quinupristin/dalfopristin, or daptomycin are valid options (278,281,292,360–363). Given the clinical efficacy and profile of adverse effects, daptomycin is probably the first-line antibiotic of choice for peritonitis episodes caused by VRE (278,363–365). Bone marrow suppression usually occurs after 10 to 14 days of linezolid therapy, and prolonged therapy may also result in neurotoxicity. One previous study showed that removal of the PD catheter within 1 week of the onset of refractory enterococcal peritonitis was associated with a significant reduction in the risk of permanent hemodialysis transfer (356). Streptococcal Species We suggest that streptococcal peritonitis be treated with appropriate antibiotics, such as IP ampicillin, for 2 weeks (2C). Streptococci frequently originate from the mouth (175), although S. bovis typically comes from the colon (366). Peritonitis episodes caused by streptococci usually respond well to antibiotic treatment (175,367), but viridans streptococcal peritonitis are more likely to be refractory (368). Cefazolin and vancomycin are often effective. Staphylococcus Aureus We suggest that Staphylococcus aureus peritonitis be treated with effective antibiotics for 3 weeks (2C). Peritonitis episodes caused by Staphylococcus aureus are often secondary to exit-site or tunnel infection, although touch contamination is also common. If the bacterial isolate is methicillin-sensitive, a first-generation cephalosporin is the drug of choice. Two retrospective studies found that the initial empiric antibiotic choice between vancomycin and cefazolin had similar clinical outcomes (369,370). If the isolate is methicillin-resistant, IP vancomycin is the drug of choice, but teicoplanin and daptomycin can be used as alternatives (371). One study showed that the use of adjuvant rifampicin for 5 to 7 days may reduce the risk for relapsing or repeat S. aureus peritonitis (369). However, rifampicin is a potent liver enzyme inducer and interaction with other concomitant medications may be problematic. Observational data suggest that treatment with effective antibiotics for 3 weeks is needed (369,370,372). Prolonged vancomycin therapy may predispose to the emergence of vancomycin-resistant S. aureus and should be avoided whenever possible. For patients with concomitant S. aureus exit-site or catheter tunnel infection, catheter removal should be considered. Corynebacterium Peritonitis We suggest that corynebacterial peritonitis be treated with effective antibiotics for 3 weeks (2C). Corynebacterium species belong to the natural flora of the skin. Infections due to Corynebacterium have been increasingly recognized over the past decades, largely due to improved recognition and microbiological techniques. In a retrospective study, Corynebacterium peritonitis often resulted in relapse or repeat episodes, catheter removal, permanent hemodialysis transfer, and death (373). Another retrospective study found that relapsing Corynebacterium peritonitis was common after a 2-week course of antibiotic treatment, but relapsing episodes can usually be cured with a 3-week course of IP vancomycin (374). For refractory Corynebacterium peritonitis, observational data suggest that catheter removal within 1 week after the onset of peritonitis significantly reduces the risk of permanent hemodialysis transfer (373). For patients with concomitant exit-site or catheter tunnel infection caused by Corynebacterium, early catheter removal should be considered. Pseudomonas Peritonitis We suggest that Pseudomonas peritonitis be treated with 2 antibiotics with different mechanisms of action and to which the organism is sensitive (e.g. IP gentamicin or oral ciprofloxacin with IP ceftazidime or cefepime) for 3 weeks (2C). We suggest that Pseudomonas peritonitis with concomitant exit-site and tunnel infection be treated with catheter removal (2D). Pseudomonas peritonitis is generally severe and often associated with infection of the catheter. Pseudomonas aeruginosa is the most common species. Retrospective studies have shown that Pseudomonas peritonitis is associated with greater frequencies of hospitalization, high rates of catheter removal and permanent hemodialysis transfer (375–377). The use of 2 anti-pseudomonal antibiotics is associated with better outcomes (377). Carbapenems, such as imipenem, meropenem, and doripenem are valid alternatives, especially if the bacterial isolate is resistant to cephalosporin and anti-pseudomonal penicillins. If fluoroquinolone is used as part of the regimen, ciprofloxacin should be used, while moxifloxacin has very little anti-pseudomonal activity. If concomitant catheter infection is present, catheter removal is often needed. Other Gram-Negative Bacteria We suggest that non-Pseudomonas gram-negative peritonitis be treated with effective antibiotics for at least 3 weeks (2C). If single gram-negative organisms are isolated, the antibiotic should be chosen according to sensitivity, safety, and convenience. It is important to note that bacteria in biofilm are considerably less sensitive than that indicated by laboratory testing (378), which may account for the high percentage of treatment failures, even though the organism appears to be sensitive to the antibiotic in vitro (379,380). Retrospective studies have shown that gram-negative peritonitis had higher risks of catheter loss and death than gram-positive episodes (379–384). In one study, recent antibiotic therapy was the major risk factor of antibiotic resistance, while ESI, and possibly recent antibiotic therapy, were associated with poor therapeutic response (382). The SPICE organisms (Serratia, Pseudomonas, indole-positive organisms such as Proteus and Providentia, Citrobacter, and Enterobacter) have amp-C beta-lactamases, which inactivate cephalosporins, and have a high risk of relapse. Although single antibiotic therapy is often effective, 1 retrospective study suggested that treatment with 2 antibiotics may reduce the risk of relapse and recurrence (382). In recent years, there has been widespread emergence of 2 antibiotic resistance mechanisms: extended-spectrum beta-lactamases (ESBLs) (385,386) and carbapenem-resistant Enterobacteriaceae (CRE) (385,387); the latter are also called Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria when the carbapenem resistance is mediated by beta-lactamases. Extended-spectrum beta-lactamases are resistant to all cephalosporins but usually susceptible to carbapenems. Carbapenem-resistant Enterobacteriaceae/KPC-producing bacteria are usually resistant to all classes of beta-lactams, usually resistant to fluoroquinolones, variably susceptible to aminoglycosides, but usually susceptible to polymyxin and colistin. The isolation of a Stenotrophomonas species, while infrequent, requires special attention, as it is sensitive to only a few antimicrobial agents (388,389). Recent treatment with carbapenems, fluoroquinolones, or third- or fourth-generation cephalosporins usually precedes Stenotrophomonas infections. Based on limited observational data, therapy with 2 antibiotics for 3 to 4 weeks is recommended (388,389). If the isolate is sensitive to trimethoprim/sulfamethoxazole, this agent should be included in the regimen. Tigecycline, polymyxin B, and colistin are other possible alternatives. Polymicrobial Peritonitis If multiple enteric organisms (multiple gram-negative or mixed gram-negative/gram-positive organisms) are grown from PD effluent, we suggest that surgical evaluation be obtained immediately when there is no prompt clinical response (1C) and that the patient be treated with metronidazole in conjunction with IP vancomycin and either IP aminoglycoside or IP ceftazidime for a minimum period of 3 weeks (2C). If multiple gram-positive organisms are grown from PD effluent, we suggest that patients be treated with effective antibiotics for 3 weeks (2C). When multiple enteric organisms are grown from the PD effluent, there is a possibility of intra-abdominal pathology. Presentation with hypotension, sepsis, lactic acidosis, or elevated dialysis effluent amylase level should also raise the possibility of abdominal catastrophe (390,391). When a surgical cause of peritonitis is suspected, the antibiotics of choice are metronidazole plus vancomycin, in combination with ceftazidime or an aminoglycoside. Monotherapy with a carbapenem or piperacillin/tazobactam may also be considered. Assessment by a surgeon is needed. Computed tomographic (CT) scan may help to identify the pathology, but a normal CT scan does not eliminate that possibility. If laparotomy is needed, the PD catheter is usually removed and antibiotics are continued via IV route. In contrast, polymicrobial peritonitis due to multiple gram-positive organisms often has a favorable prognosis (392,393). Their clinical behavior is similar to peritonitis episodes caused by single gram-positive organisms and the etiology may well be touch contamination. Antibiotic therapy is often effective without catheter removal (392). Culture-Negative Peritonitis We suggest that negative effluent cultures on day 3 warrant a repeat dialysis effluent WBC count with differential (2D). If the culture-negative peritonitis is resolving at day 3, we suggest discontinuing aminoglycoside therapy and continuing treatment with gram-positive coverage (e.g. first-generation cephalosporin or vancomycin) for 2 weeks (2C). If the culture-negative peritonitis is not resolving at day 3, we suggest special culture techniques be considered for isolation of unusual organisms (2C). Recent antibiotic usage and technical problems of culturing the specimen are the major reasons for negative effluent cultures (394–396). If PD effluent yields no growth after 3 days, a repeat WBC count with differential should be obtained. If the repeat cell count indicates that the infection has not resolved, special culture techniques may be considered for the isolation of unusual organisms (e.g. mycobacteria, nocardia, legionella, filamentous fungus, and other fastidious bacteria). This would require close liaison with the microbiology laboratory. Many culture-negative peritonitis episodes are probably caused by gram-positive organisms. If the patient improves clinically, initial therapy should be continued (394–396). Duration of therapy should be 2 weeks if the effluent clears promptly. In contrast, if there is suboptimal response after 5 days of empirical antibiotics, catheter removal should be strongly considered. Fungal Peritonitis We recommend immediate catheter removal when fungi are identified in PD effluent (1C). We suggest that treatment with an appropriate anti-fungal agent be continued for at least 2 weeks after catheter removal (2C). Fungal peritonitis is a serious complication with high rates of hospitalization, catheter removal, transfer to hemodialysis, and death (397–400). Initial therapy is traditionally a combination of amphotericin B and flucytosine. However, IP amphotericin causes chemical peritonitis and pain, while IV administration has poor peritoneal bioavailability. In addition, flucytosine is not widely available. If flucytosine is used, regular monitoring of serum concentration is necessary to avoid bone marrow toxicity. Peak serum flucytosine levels, measured 1 – 2 hours after an oral dose, should be 25 – 50 mcg/mL (401,402). Other agents of choice include fluconazole, an echinocandin (e.g. caspofungin, micafungin, or anidulafungin), posaconazole, and voriconazole. Although fluconazole is commonly used, the prevalence of azole resistance is increasing (403). Fluconazole only has activity against Candida species and Cryptococcus. Echinocandins have been advocated for the treatment of fungal peritonitis caused by Aspergillus species and non-albicans Candida species, or in patients intolerant to other antifungal therapies (297,298,398). Caspofungin has been used successfully as monotherapy or in combination with amphotericin (297,298). Posaconazole and voriconazole have been successfully used for the treatment of peritonitis caused by filamentous fungi (287,300,301). Irrespective of the choice of anti-fungal agent, observational studies suggest that prompt catheter removal probably improves outcome and reduces mortality (300,301,397,398,400,404). Anti-fungal agents should be continued after catheter removal for at least 2 weeks. A recent study suggested that around one-third of patients could return to PD (399). Tuberculous Peritonitis Although classical symptoms of fever, abdominal pain, and cloudy effluent may occur with tuberculous peritonitis, the diagnosis should be considered in any patient with refractory or relapsing peritonitis with negative bacterial cultures. Similar to bacterial peritonitis, most cases of tuberculous peritonitis have PMN in the dialysis effluent at initial presentation, but lymphocytosis in the dialysis effluent usually becomes obvious later. Ziehl-Neelsen stain examination of the PD effluent is often unrevealing, and conventional culture technique (e.g. Löwenstein-Jensen agar) is slow and not sufficiently sensitive. The time to develop a positive culture is considerably decreased in fluid medium (e.g. Septi-Chek, BACTEC; Becton Dickinson, NJ, USA). Overall diagnostic yield could be improved by centrifuging a large volume of effluent (50 to 100 mL), followed by culturing the sediment in both solid and fluid media. Alternatively, mycobacterial DNA PCR can be performed on dialysis effluent, although false-positives are not uncommon (405). Laparoscopy with biopsy of the peritoneum or omentum has also been advocated for rapid diagnosis if the index of suspicion is high (406). The treatment protocol should be based on general protocols for treatment of tuberculosis but is often started with 4 drugs: rifampicin, isoniazid, pyrazinamide, and ofloxacin. A previous study showed that rifampicin levels in PD effluent are often low (407). Intraperitoneal rifampicin treatment has been advocated but is not available in many countries. In general, pyrazinamide and ofloxacin could be stopped after 2 months, while rifampicin and isoniazid should be continued for a total of 12 to 18 months (407–413). Pyridoxine (50 to 100 mg/day) should be given to avoid isoniazid-induced neurotoxicity. On the other hand, long-term use of pyridoxine at a higher dose (e.g. 200 mg daily) is in itself associated with neuropathy and should be avoided. Streptomycin, even in reduced doses, may cause ototoxicity after prolonged use and should be avoided. Ethambutol is associated with a high risk of optic neuritis in dialysis patients and must be used with appropriate dosage reduction. Previous reports suggest a dose of 15 mg/kg every 48 hours or thrice weekly for up to 2 months (414). The optimal treatment for drug-resistant tuberculous peritonitis remains unknown. Many patients respond to anti-tuberculous therapy without catheter removal (407–413,415). However, it is important to differentiate patients with miliary tuberculosis, whose peritonitis is part of the disseminated disease, from those with isolated tuberculous peritonitis without extraperitoneal infection, because the duration of anti-tuberculous therapy is different. Non-Tuberculous Mycobacterial Peritonitis Data on peritonitis caused by non-tuberculous mycobacteria are limited but may be increasing (21,416–422). It is not uncommon for non-tuberculous mycobacteria to be misidentified as gram-positive diphtheroids. Over half of the isolates are rapidly growing species, such as M. fortuitum and M. chelonae (420), and often become positive on routine bacteriologic cultures in 3 to 5 days. It has been postulated that extensive use of topical gentamicin ointment for exit-site infection may predispose patients to non-tuberculous mycobacterial infection of the exit site (144). The treatment regimen for non-tuberculous mycobacterial peritonitis is not well established and requires individualized protocols based on susceptibility testing. Catheter removal is usually necessary, and experience with non-removal is limited (420–422). The type and duration of antibiotic therapy are variable, and the optimal treatment regimen is poorly defined and depends on species and drug susceptibilities (416–422). Catheter Removal and Re-Insertion We recommend that PD catheters be removed for refractory, relapsing, or fungal peritonitis unless there are clinical contraindications (1C). We suggest that it is appropriate to consider return to PD for many patients who have had their catheter removed for refractory, relapsing, or fungal peritonitis (2C). We suggest that if re-insertion of a new catheter is attempted after a PD catheter is removed for refractory, relapsing, or fungal peritonitis, it be performed at least 2 weeks after catheter removal and complete resolution of peritoneal symptoms (2D). Indications for catheter removal are summarized in Table 8. For refractory peritonitis and fungal peritonitis, simultaneous re-insertion of a new PD catheter is not recommended, and patients should be put on temporary hemodialysis. Observational studies suggest that effective antibiotics should be continued for at least 2 weeks after catheter removal for refractory peritonitis (423,424). TABLE 8 Indications for Catheter Removal After severe episodes of peritonitis, around 50% of patients could potentially return to PD (423–425). An ANZDATA Registry study demonstrated that return to PD after catheter removal and temporary hemodialysis for peritonitis was not associated with inferior patient-level clinical outcomes when compared with other patients who either never required hemodialysis transfer for peritonitis or who had permanent hemodialysis transfer for peritonitis (426). Furthermore, subsequent peritonitis-free, technique and patient survival following return to PD were not associated with organism type or duration of time from hemodialysis transfer to PD restart (426). There are few data on the optimal duration between catheter removal for peritonitis and re-insertion of a new catheter. Observational studies suggest a minimum period of 2 to 3 weeks (423–425), although some would recommend later re-insertion in cases of fungal peritonitis (397,398). Re-insertion of a new catheter should be done by laparoscopic or mini-laparotomy approach so that adhesion can be directly visualized. Ultrafiltration problems are common after return to PD (423,424). A small proportion of patients with PD-related peritonitis develop recurrent intra-abdominal collection that requires percutaneous drainage after catheter removal (427). The chance of a successful return to PD is very low in this group of patients, and direct conversion to long-term hemodialysis should be considered (427). Future Research There are some new antibiotics that, to the best of our knowledge, have not been tried for the treatment of PD-related peritonitis. For example, ceftaroline has good coverage of gram-negative bacteria and is also active against MRSA and methicillin-resistant coagulase-negative staphylococci. The pharmacokinetic data of many new antibiotics, administered either systemically or IP, are much needed and some are in the pipeline (428). Many data on antibiotic stability in PD solutions are old and need to be repeated in new PD solutions. Pharmacodynamic investigations specific to PD-related peritonitis are scarce. The impact of antibiotic resistance also requires further study. MALDI-TOF mass spectrometry has recently been used in academic facilities to identify microorganisms in biologic fluids. This technique may shorten the time to species identification and also help to identify rare or unknown pathogens. The application of MALDI-TOF mass spectrometry and other novel techniques to the diagnosis of PD peritonitis deserves further study. Clinical trials are also required in order to assess the efficacy and safety of various treatment regimens, especially for the treatment of peritonitis in APD. Outcomes to be examined should include not only resolution without catheter removal, but also the duration of peritoneal inflammation, relapsing and repeat episodes, as well as the change in peritoneal solute transport status after resolution of peritonitis. Further studies are also needed on primary and secondary prevention of peritonitis. The efficacy of treating many “modifiable” risk factors has not been formally tested. Research on the biology and management of catheter biofilm is also needed. Finally, whilst PD training is widely acknowledged as crucial to achieving good clinical outcomes in PD, high-level evidence guiding how, where, when, and by whom PD training should be performed is lacking. Research in this area should explicitly detail the training curriculum and approach (rather than vaguely alluding to adult-learning principles) to permit generalizability of study findings. Disclosures CCS receives research grant and consultancy amounts from Baxter Healthcare. AF received consultant and speaker fees from Baxter Healthcare. EG is a member of the advisory board for Baxter Healthcare and Nx Stage and received honoraria from Baxter Healthcare, Nx Stage, Shire, Alexion and Sanofi. DJ has previously received consultancy fees, research funding, travel sponsorship and research funding from Baxter Healthcare and Fresenius Medical Care. He has also received travel sponsorship from Amgen. The others declare no conflict of interests.
              • Record: found
              • Abstract: found
              • Article: not found

              Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.

              Peritonitis is a major complication of peritoneal dialysis, but the relationship between peritonitis and mortality among these patients is not well understood. In this case-crossover study, we included the 1316 patients who received peritoneal dialysis in Australia and New Zealand from May 2004 through December 2009 and either died on peritoneal dialysis or within 30 days of transfer to hemodialysis. Each patient served as his or her own control. The mean age was 70 years, and the mean time receiving peritoneal dialysis was 3 years. In total, there were 1446 reported episodes of peritonitis with 27% of patients having ≥ 2 episodes. Compared with the rest of the year, there were significantly increased odds of peritonitis during the 120 days before death, although the magnitude of this association was much greater during the 30 days before death. Compared with a 30-day window 6 months before death, the odds for peritonitis was six-fold higher during the 30 days immediately before death (odds ratio, 6.2; 95% confidence interval, 4.4-8.7). In conclusion, peritonitis significantly associates with mortality in peritoneal dialysis patients. The increased odds extend up to 120 days after an episode of peritonitis but the magnitude is greater during the initial 30 days.

                Author and article information

                Blood Purif
                Blood Purification
                S. Karger AG
                February 2022
                12 October 2021
                : 51
                : 3
                : 280-287
                [_a] aDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, China
                [_b] bDepartment of Nephrology, Second Part of the First Hospital of Jilin University, Changchun, China
                [_c] cDepartment of Nephrology, Jilin Central Hospital, Jilin, China
                [_d] dDepartment of Nephrology, Jilin FAW General Hospital, Changchun, China
                514938 Blood Purif 2022;51:280–287
                © 2021 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                : 05 August 2020
                : 01 February 2021
                Page count
                Figures: 3, Tables: 2, Pages: 8
                Peritoneal Dialysis – Research Article

                Cardiovascular Medicine,Nephrology
                Peritoneal dialysis-associated peritonitis,Diabetes mellitus,Early-onset peritonitis,End-stage renal disease,Peritoneal dialysis


                Comment on this article